Mission Statement

NeuroVigil is a global neurotechnology pioneer which develops proprietary non-invasive brain monitors and advanced machine learning algorithms to detect a constellation of biomarkers of pathologies in asymptomatic individuals, such as people with neurodegeneration, adverse drug side effects or brain cancer, and to ascertain intent including, at the request of the late Stephen Hawking, in individuals who cannot otherwise communicate. This arsenal of technologies does not require any non-human animal experimentation.

The Company successfully went to market in 2009, garnered research contracts with elite pharmaceutical companies, and spearheads a growing international preventive health conglomerate of leading innovators and entrepreneurs.

The company was founded and is led by Philip Low.